References
- Napolitano M, Megna M, Timoshchuk EA, et al. Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment. Clin Cosmet Investig Dermatol. 2017;10:105–115.
- Wolff K, Johnson RA, Saavedra AP, et al. Fitzpatrick’s color atlas and synopsis of clinical dermatology. 8th ed. New York (NY): McGraw-Hill Education; 2017.
- Jemec GB. Quality of life considerations and pain management in hidradenitis suppurativa. Semin Cutan Med Surg. 2017;36:75–78.
- Deckers IE, Janse IC, van der Zee HH, et al. Hidradenitis suppurativa (HS) is associated with low socioeconomic status (SES): a cross-sectional reference study. J Am Acad Dermatol. 2016;75:755–759e1.
- Dauden E, Lazaro P, Aguilar MD, et al. Recommendations for the management of comorbidity in hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2017. DOI:10.1111/jdv.14517
- Shalom G. Hidradenitis suppurativa: epidemiology, clinical features, associated comorbidities and treatment. G Ital Dermatol Venereol. 2017;152:46–57.
- Shalom G, Freud T, Harman-Boehm I, et al. Hidradenitis suppurativa and metabolic syndrome: a comparative cross-sectional study of 3207 patients. Br J Dermatol. 2015;173:464–470.
- Melnik BC, Plewig G. Impaired Notch signalling: the unifying mechanism explaining the pathogenesis of hidradenitis suppurativa (acne inversa). Br J Dermatol. 2013;168:876–878.
- Wolk K, Wenzel J, Tsaousi A, et al. Lipocalin-2 is expressed by activated granulocytes and keratinocytes in affected skin and reflects disease activity in acne inversa/hidradenitis suppurativa. Br J Dermatol. 2017. DOI:10.1111/bjd.15424
- van der Zee HH, de Ruiter L, van den Broecke DG, et al. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol. 2011;164:1292–1298.
- Wolk K, Warszawska K, Hoeflich C, et al. Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa. J Immunol. 2011;186:1228–1239.
- Moran B, Sweeney CM, Hughes R, et al. Hidradenitis suppurativa is characterised by dysregulation of the Th17:Treg cell axis, which is corrected by anti-TNF therapy. J Invest Dermatol. 2017;137:2389–2395.
- Schlapbach C, Hanni T, Yawalkar N, et al. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2011;65:790–798.
- Boniface K, Blom B, Liu YJ, et al. From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited. Immunol Rev. 2008;226:132–146.
- Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129:1339–1350.
- Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 2003;421:744–748.
- Murphy CA, Langrish CL, Chen Y, et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med. 2003;198:1951–1957.
- van der Zee HH, Laman JD, Boer J, et al. Hidradenitis suppurativa: viewpoint on clinical phenotyping, pathogenesis and novel treatments. Exp Dermatol. 2012;21:735–739.
- Banerjee A, McNish S, Shanmugam VK. Interferon-gamma (IFN-gamma) is elevated in wound exudate from hidradenitis suppurativa. Immunol Invest. 2017;46:149–158.
- Dreno B, Khammari A, Brocard A, et al. Hidradenitis suppurativa: the role of deficient cutaneous innate immunity. Arch Dermatol. 2012;148:182–186.
- Kuwabara T, Ishikawa F, Kondo M, et al. The Role of IL-17 and related cytokines in inflammatory autoimmune diseases. Mediators Inflamm. 2017;2017:3908061.
- Jimenez-Gallo D, de la Varga-Martinez R, Ossorio-Garcia L, et al. The clinical significance of increased serum proinflammatory cytokines, C-reactive protein, and erythrocyte sedimentation rate in patients with hidradenitis suppurativa. Mediators Inflamm. 2017;2017:2450401.
- Lynde CW, Poulin Y, Vender R, et al. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol. 2014;71:141–150.
- Weber P, Seyed Jafari SM, Yawalkar N, et al. Apremilast in the treatment of moderate to severe hidradenitis suppurativa: a case series of 9 patients. J Am Acad Dermatol. 2017;76:1189–1191.
- Schindler R, Gelfand JA, Dinarello CA. Recombinant C5a stimulates transcription rather than translation of interleukin-1 (IL-1) and tumor necrosis factor: translational signal provided by lipopolysaccharide or IL-1 itself. Blood. 1990;76:1631–1638.
- Sockolov ME, Alikhan A, Zargari O. Non-psoriatic dermatologic uses of monoclonal antibody therapy. J Dermatolog Treat. 2009;20:319–327.
- Monfrecola G, Balato A, Caiazzo G, et al. Mammalian target of rapamycin, insulin resistance and hidradenitis suppurativa: a possible metabolic loop. J Eur Acad Dermatol Venereol. 2016;30:1631–1633.
- Kumari R, Thappa DM. Role of insulin resistance and diet in acne. Indian J Dermatol Venereol Leprol. 2013;79:291–299.
- Tsaousi A, Witte E, Witte K, et al. MMP8 is increased in lesions and blood of acne inversa patients: a potential link to skin destruction and metabolic alterations. Mediators Inflamm. 2016;2016:4097574.
- Deckers IE, Prens EP. An update on medical treatment options for hidradenitis suppurativa. Drugs. 2016;76:215–229.
- Hoffman LK, Ghias MH, Lowes MA. Pathophysiology of hidradenitis suppurativa. Sem Cutan Med Surg. 2017;36:47–54.
- Kimball AB, Sobell JM, Zouboulis CC, et al. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol. 2016;30:989–994.
- AbbVie. Humira (adalimumab) [Internet]. 2001. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/125057s0110lbl.pdf.
- ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT01468207. Efficacy and safety study of adalimumab in treatment of hidradenitis suppurativa (PIONEER I). 2011. Available from: https://clinicaltrials.gov/ct2/show/NCT01468207?cond=Efficacy+and+Safety+ Study+of+Adalimumab+in+Treatment+of+Hidradenitis+Suppurativa&rank =1.
- ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT01468233. Efficacy and safety study of adalimumab in the treatment of hidradenitis suppurativa (PIONEER II). 2011. Available from: https://clinicaltrials.gov/ct2/show/NCT01468233?cond=Efficacy+and+Safe-ty+Study+of+Adalimumab+in+Treatment+of+Hidradenitis+Suppurativa&rank =2.
- Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375:422–434.
- ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT01635764. Open-label study of the safety and efficacy of adalimumab in the treatment of hidradenitis suppurativa. 2012. Available from: https://clinicaltrials.gov/ct2/show/NCT01635764.
- Zouboulis C, Okun MM, Gniadecki R, et al. Adalimumab efficacy in hidradenitis suppurativa patients is sustained at least three years with weekly dosing: results from a phase 3 open-label extension study (PIONEER). J Am Acad Dermatol. 2017;76:AB33.
- ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT02904902. Open-label study of adalimumab in Japanese subjects with hidradenitis suppurativa. 2016. Available from: https://clinicaltrials.gov/ct2/show/NCT02904902.
- ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT02808975. Safety and efficacy of humira (adalimumab) for hidradenitis suppurativa (HS) peri-surgically (SHARPS study). 2016. Available from: https://clinicaltrials.gov/ct2/show/NCT02808975.
- ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT03001115. Post-marketing surveillance of adalimumab in Korean hidradenitis suppurativa subjects. 2016. Available from: https://clinicaltrials.gov/ct2/show/NCT03001115.
- ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT02896920. Canadian humira post marketing observational epidemiological study: assessing humira real-life effectiveness and impact on HS burden of illness. 206. Available from: https://clinicaltrials.gov/ct2/show/NCT02896920.
- ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT02739828. Post marketing observational study (PMOS) to assess quality of life in Swedish hidradenitis suppurativa (HS) Patients. 2016. Available from: https://clinicaltrials.gov/ct2/show/NCT02739828.
- ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT02786576. Effectiveness of adalimumab in moderate to severe hidradenitis suppurativa patients – a multi country study in real life setting. 2016. Available from: https://clinicaltrials.gov/ct2/show/NCT02786576.
- Amgen. Enbrel (etanercept) [Internet]. 2012. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103795s5503lbl.pdf.
- Alldred A. Etanercept in rheumatoid arthritis. Expert Opin Pharmacother. 2001;2:1137–1148.
- ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT00108991. Etanercept for treatment of hidradenitis. 2005. Available from: https://clinicaltrials.gov/ct2/show/NCT00107991.
- ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT00949546. Treatment of hidradenitis suppurativa using etanercept. 2009. Available from: https://clinicaltrials.gov/ct2/show/NCT00949546.
- Adams DR, Yankura JA, Fogelberg AC, et al. Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol. 2010;146:501–504.
- Lee RA, Dommasch E, Treat J, et al. A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 2009;60:565–573.
- ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT00329823. Etanercept in hidradenitis suppurativa. 2006. Available from: https://clinicaltrials.gov/ct2/show/NCT00329823.
- Cusack C, Buckley C. Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol. 2006;154:726–729.
- Janssen Biotech. Remicade (infliximab) [Internet]. 2013. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103772s5359lbl.pdf.
- ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT00795574. Study to assess the safety and efficacy of infliximab to treat hidradenitis suppurtativa. 2008. Available from: https://clinicaltrials.gov/ct2/show/NCT00795574.
- Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62:205–217.
- Swedish Orphan Biovitrum AB. Kineret (anakinra) [Internet]. 2012. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103950s5136lbl.pdf.
- ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT01516749. Anakinra as a treatment for hydradenitis suppurativa. 2012. Available from: https://clinicaltrials.gov/ct2/show/NCT01516749.
- Tzanetakou V, Kanni T, Giatrakou S, et al. Safety and efficacy of anakinra in severe hidradenitis suppurativa. JAMA Dermatol. 2016;152:52–59.
- ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT01558375. Anakinra in hidradenitis suppurativa. 2012. Available from: https://clinicaltrials.gov/ct2/show/NCT01558375.
- ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT01838499. Assessment of the safety, tolerability and efficacy of MEDI8968 in subjects with moderate to severe hidradenitis suppurativa. 2013. Available from: https://clinicaltrials.gov/ct2/show/NCT01838499.
- Reichert JM. Antibodies to watch in 2017. MAbs. 2017;9:167–181.
- ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT02643654. MABp1 in hidradenitis suppurativa refractory to adalimumab. 2015. Available from: https://clinicaltrials.gov/ct2/show/NCT02643654.
- ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT02421172. Efficacy, safety, and pharmacokinetics study of CJM112 in hidradenitis suppurativa patients. 2015. Available from: https://clinicaltrials.gov/ct2/show/NCT02421172.
- Novartis Pharma AG. Cosentyx (secukinumab) [Internet]. 2015. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125504s001s002lbl.pdf.
- Thorlacius L, Theut Riis P, Jemec GBE. Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report. Br J Dermatol. 2017. DOI:10.1111/bjd.15769
- ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT03099980. Exploratory trial evaluating cosentyx (secukinumab) for patients with moderate-to-severe hidradenitis suppurativa. 2017. Available from: https://clinicaltrials.gov/ct2/show/NCT03099980.
- ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT03248531. A study to test the efficacy, safety and pharmacokinetics of bimekizumab in subjects with moderate to severe hidradenitis suppurativa. 2017. Available from: https://clinicaltrials.gov/ct2/show/NCT03248531.
- Janssen Biotech. Stelara (ustekinumab) [Internet]. 2016. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761044lbl.pdf.
- Gulliver WP, Jemec GB, Baker KA. Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2012;26:911–914.
- Blok JL, Li K, Brodmerkel C, et al. Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum. Br J Dermatol. 2016;174:839–846.
- ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT01704534. A proof of concept study to evaluate the effectiveness of ustekinumab in hidradenitis suppurativa. 2012. Available from: https://clinicaltrials.gov/ct2/show/NCT01704534.
- Celgene Corporation. Otezla (apremilast) [Internet]. 2014. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206088s000lbl.pdf.
- ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT03049267. Short-term safety, efficacy and mode of action of apremilast in moderate suppurative hidradenitis. 2017. Available from: https://clinicaltrials.gov/ct2/show/NCT03049267.
- ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT02695212. Single center study of apremilast for the treatment of hidradenitis suppurativa. 2016. Available from: https://clinicaltrials.gov/ct2/show/NCT02695212.
- Genentech. RAPTIVA [efalizumab] [Internet]. 2009. Available from: https://www.fda.gov/downloads/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm143346.pdf.
- ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT00134134. Efficacy and safety of efalizumab in the treatment of moderate-severe hydradenitis auppurativa. 2005. Available from: https://clinicaltrials.gov/ct2/show/NCT00134134.
- Strober BE, Kim C, Siu K. Efalizumab for the treatment of refractory hidradenitis suppurativa. J Am Acad Dermatol. 2007;57:1090–1091.
- Pugashetti R, Koo J. Efalizumab discontinuation: a practical strategy. J Dermatolog Treat. 2009;20:132–136.
- ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT03001622. Studying complement inhibition in patients with moderate to severe hidradenitis suppurativa. 2016. Available from: https://clinicaltrials.gov/ct2/show/NCT03001622.
- Reeder VJ, Mahan MG, Hamzavi IH. Ethnicity and hidradenitis suppurativa. J Invest Dermatol. 2014;134:2842–2843.
- Vazquez BG, Alikhan A, Weaver AL, et al. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol. 2013;133:97–103.
- ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT00918255. Study of adalimumab in subjects with moderate to severe chronic hidradenitis suppurativa. 2009. Available from: https://clinicaltrials.gov/ct2/show/NCT00918255.
- ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT00827996. To assess the efficacy and safety of adalimumab in subjects with moderate to severe hidradenitis suppurativa. 2009. Available from: https://clinicaltrials.gov/ct2/show/NCT00827996.